Form 4: United Therapeutics CEO Executes Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at an exercise price of $146.03 per share.
• Following the exercise, the reporting person sold the 9,500 shares in multiple transactions on May 5, 2026.
• The sales were executed at weighted average prices ranging from $567.27 to $581.68 per share.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management rather than a change in company outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive selling.
• The CEO maintains a significant beneficial ownership stake in the company, including 40,513 shares held directly and substantial holdings across various family trusts.

Negatives

• The sale of shares by a top executive can sometimes be perceived by the market as a signal of reduced confidence, though this was pre-planned.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026, which may result in ongoing selling pressure.

Future Outlook

The reporting person's 10b5-1 plan remains active, with the potential for further exercises and sales of up to 1,734,410 stock options through December 31, 2026.

Management Comments

• The transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice in the biotech industry for liquidity and diversification, and this specific filing reflects a routine execution of a long-term compensation plan.

Comparison to Industry Standards

• The use of 10b5-1 plans is a best-practice standard for corporate executives to avoid potential conflicts of interest or accusations of insider trading.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive wealth management strategies in large-cap pharmaceutical companies.

Related Party Transactions

• Shares held in various family trusts where the reporting person or spouse shares investment power or acts as trustee.

Stakeholder Impact

• Minimal impact expected as the sales are part of a pre-disclosed, systematic trading plan.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Biotech, Executive Compensation